Predictheon, whose Predictive Decision Assistant innovation saw them secure part of a US$25,000 prize fund and prime exhibition space at WHX 2027 ...

Orca-T outcomes in patients with myelodysplastic syndromes to be presented for the first time; includes retrospective comparison to PTCy Additional presentations will highlight the combination of Orca ...

Accelerated drug discovery and development platform Converge Bio Inc. today announced it has raised $25 million in early-stage funding to develop better drugs for pharmaceutical companies and open up ...

Artificial intelligence is moving quickly into drug discovery as pharmaceutical and biotech companies look for ways to cut years off R&D timelines and increase the chances of success amid rising costs ...

Tech companies are building data centers as quickly as possible to run AI. These facilities are controviersial because they use copious amounts of electricity and might tax an electrical grid that in ...

Jan 6 (Reuters) - Variant Bio, a private biotech firm, said on Tuesday it has launched a platform that uses artificial intelligence on genetic data to discover new drug candidates to send into human ...

MENLO PARK, Calif.--(BUSINESS WIRE)--Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced new data ...

The rollout of edge AI is creating new security risks due to a mix of small language models (SLMs), their integration into increasingly complex hardware, and the behavior and interactions of both over ...

The explosive growth of data centers could threaten the stability of the electrical grid this winter, according to an industry overseer. Across North America, demand for electricity this winter is ...

Caralynn Nowinski Collens, Ramille Shah, and Adam Jakus spent years developing an innovative technology to regenerate injured bone. The results, they thought, were . . . okay. The company they founded ...

Third Arc Bio is paying $5 million upfront to use Adagene’s tech in hopes of creating two new masked T-cell engagers. Down the line, Adagene could make up to $840 million in development and commercial ...